1.01

2.02% 0.02

Pre-market: 1.00 -0.01 -0.99%

Revelation Biosciences Inc (REVB)

Overview News Price History Financials Discussions Forecast Stock Split

Revelation Biosciences Inc stock is traded at $1.01, with a volume of 22,827. It is up +2.02% in the last 24 hours and up +5.21% over the past month. Revelation Biosciences Inc is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. The company is developing a pipeline of potential products based on Gemini, which is its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA). PHAD is a small fragment of lipopolysaccharide (LPS) that stimulates TLR4 and leads to controlled production of multiple cytokines and chemokines that modulate the innate and adaptive immune response. The company operates through one reportable segment focused on the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system.

Previous Close:

$0.99

Open:

$1.02

24h Volume:

22,827

Relative Volume:

0.33

Market Cap:

$3.95M

Revenue:

Net Income/Loss:

$-8.91M

P/E Ratio:

-0.026

EPS:

-38.8702

Net Cash Flow:

$-8.27M

1W Performance:

-7.34%

1M Performance:

+5.21%

6M Performance:

-76.07%

1Y Performance:

-70.62%

1-Day Range:

$0.98

$1.0356

1-Week Range:

$0.98

$1.085

52-Week Range:

$0.875

$12.88

Revelation Biosciences Inc Stock (REVB) Company Profile

Name

Revelation Biosciences Inc

Sector

Healthcare (1100)

Industry

Biotechnology (613)

Phone

650-800-3717

Address

4660 LAJOLLA VILLAGE DRIVE, SAN DIEGO

Employee

Twitter

Next Earnings Date

2026-05-14

Latest SEC Filings

REVB's Discussions on Twitter

Compare REVB vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
REVB Revelation Biosciences Inc	1.01	3.87M	0	-8.91M	-8.27M	-38.87
VRTX Vertex Pharmaceuticals Inc	442.96	113.41B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	611.34	66.62B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	882.41	55.43B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	292.16	40.46B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	148.49	31.73B	742.00K	-1.37B	-1.07B	-7.0731

Revelation Biosciences Inc Stock (REVB) Latest News

Jun 04, 2026

Revelation Biosciences forms advisory board for AKI trial - Investing.com

Jun 04, 2026

Jun 03, 2026

Revelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Newark Advocate

Jun 03, 2026

Jun 02, 2026

Revelation Biosciences expands AKI advisory board - Investing.com UK

Jun 02, 2026

Jun 01, 2026

Revel Releases Updated Corporate Presentation and Posts It to Website - TradingView

Jun 01, 2026

Revelation Biosciences (NASDAQ: REVB) furnishes new corporate presentation - Stock Titan

Jun 01, 2026

Revelation Biosciences expands AKI advisory board By Investing.com - Investing.com South Africa

Jun 01, 2026

Revelation Biosciences Expands Acute Kidney Injury Advisory Board - The Joplin Globe

Jun 01, 2026

May 29, 2026

REVB Q1 2026 Earnings: Wider-Than-Expected Loss Highlights Pre-Revenue StageSubscription Growth Report - newsline.com

May 29, 2026

Revelation Biosciences (REVB) Stock Price, News & Analysis - MarketBeat

May 29, 2026

May 28, 2026

REVB Q1 2026 Earnings: Significant EPS Miss as Cash Burn Continues Without RevenueReturn On Assets - thelegaladvocate.com

May 28, 2026

May 27, 2026

Revelation Biosciences (REVB) Inches Higher, Holding Above Key Support at $1.02Bear Pennant - The Legal Advocate

May 27, 2026

REVB Q1 2026 Earnings: Significant EPS Miss Amid Early-Stage DevelopmentEarnings Revision Downgrade - The Legal Advocate

May 27, 2026

REVB Q1 2026 Earnings: Staggering EPS Miss Highlights Ongoing Clinical Development CostsBook Value Growth - The Legal Advocate

May 27, 2026

May 26, 2026